Working… Menu

Palifermin After Haploidentical PBSCT (KGF Haplo Allo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00570999
Recruitment Status : Withdrawn
First Posted : December 11, 2007
Last Update Posted : May 10, 2012
Information provided by:
European Group for Blood and Marrow Transplantation

Brief Summary:

This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are randomised to receive either placebo or a keratinocyte growth factor (Palifermin or Kepivance®).

The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also been suggested to have an ability to help improve the reconstitution, or development, of the immune system after the transplantation.

The hypothesis is that the patients T-cell dependent humoral immune response to recall antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo control group

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma or Hodgkin's Disease Acute Leukaemia Myelodysplastic Syndrome Chronic Myeloid Leukemia Osteomyelofibrosis Drug: Palifermin Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation
Study Start Date : February 2008
Estimated Study Completion Date : January 2013

Arm Intervention/treatment
Experimental: Arm A
Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
Drug: Palifermin
60 mg/kg/day
Other Names:
  • Keratinocyte growth factor
  • Kepivacine

Placebo Comparator: Arm B
Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
Other: Placebo
1,2 mL once daily
Other Name: 0.9% saline

Primary Outcome Measures :
  1. To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™) [ Time Frame: at study day +270 (20 days after the third Prevenar injection) ]

Secondary Outcome Measures :
  1. To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation [ Time Frame: at study days: +240 ]
  2. To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation [ Time Frame: Study days +210, +240, +270 ]
  3. To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections [ Time Frame: at 2 years ]
  4. To assess drug related safety [ Time Frame: at 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or complete remission
  • ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1 or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS)
  • CML in chronic or accelerated phase
  • Osteomyelofibrosis (OMF)
  • Hodgkin lymphoma (HD) in partial or complete remission
  • Age ≥18 years, ≤ 65 years
  • ECOG status ≤2
  • Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior local radiotherapy is allowed except radiation involving the thymus
  • Adequate pulmonary function
  • Left ventricular ejection fraction (LVEF) >30%
  • Haploidentical related donor
  • Failure to find matched related or matched unrelated donor and urgently requiring transplantation
  • Planned conditioning regimen per Aversa or Würzburg protocol
  • Women must be post-menopausal, sterile or use effective contraception and have a negative pregnancy test at study entry (β-HCG neg)
  • Signed informed consent


  • Healthy family member
  • Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3 HLA allele(s) on the unshared haplotype
  • Donors must be capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central venous catheter should leukapheresis via peripheral vein be inadequate.
  • Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell collection or should patient fail to demonstrate sustained engraftment
  • Signed informed consent

Exclusion Criteria:


  • History of or concurrent cancer (< 5 years ago) other than those named in inclusion criteria
  • Primary chemorefractory disease
  • CML in blast crisis
  • MM with no or minor response to previous treatment
  • Prior treatment with palifermin, or other keratinocyte growth factors
  • Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component of the product
  • Documented hypersensitivity to Prevenar vaccine or its components
  • Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous transplantation
  • Prior total body irradiation
  • Post thymectomy
  • Major anticipated illness or organ failure incompatible with survival from PBPC transplantation
  • Active chronic skin disease requiring therapy
  • Active inflammatory bowel disease requiring therapy
  • Active uncontrolled infection
  • Sero-positive HIV
  • Pregnancy or breast-feeding
  • Active invasive fungal tissue infection (EORTC criteria)
  • 30 days or less since receiving an investigational product or device in another clinical trial
  • Concurrent enrolment in another trial is not permitted unless the purpose is for long-term follow-up/survival data only, or observational only
  • Chronic pancreatitis or history of acute pancreatitis within 1 year prior to transplant
  • Psychiatric disorder associated with incompliance
  • Myocardial infarction less than 3 months pre enrolment or EF <30% as measured in echocardiography/laevoventriculography
  • Infusion of retrovirally or other transduced cells are not permitted.
  • Planned intravenous application of immunoglobulins is contraindicated throughout the study period.
  • Donor lymphocyte infusions are not allowed.


  • A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis infection.
  • Evidence of any other active infection
  • Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders, chronic inflammatory diseases) posing a health risk for peripheral blood stem cell harvest
  • Hematopoietic or marrow function related disease interfering with the collection of sufficient numbers of normal progenitor cells
  • Pregnancy or breast-feeding
  • Any malignancy besides basal cell epithelioma or cured malignancy < 5 years ago
  • Psychiatric disorder associated with incompliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00570999

Layout table for location information
Dr Ruth Seggewiss
Würzburg, Germany, 97080
Sponsors and Collaborators
European Group for Blood and Marrow Transplantation
Layout table for investigator information
Study Chair: Ruth Seggewiss, MD University Hospital of Würzburg
Layout table for additonal information
Responsible Party: Kim Champion, EBMT (European Group for Blood and Marrow Transplantation) Identifier: NCT00570999    
Other Study ID Numbers: EudraCt: 2007-003241-32
First Posted: December 11, 2007    Key Record Dates
Last Update Posted: May 10, 2012
Last Verified: May 2012
Keywords provided by European Group for Blood and Marrow Transplantation:
Peripheral blood stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hodgkin Disease
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Myeloid
Myeloproliferative Disorders
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action